Researchers predict ‘friction’ between payers, physicians, patients over cost of B-VEC

The FDA’s broad indication for the use of beremagene geperpavec therapy for the treatment of dystrophic epidermolysis bullosa may have large financial implications for payers, according to a study.
In May 2023, the FDA approved the first topical gene therapy, beremagene geperpavec (B-VEC; Vyjuvek, Krystal Biotech), for the treatment of autosomal recessive and autosomal dominant dystrophic epidermolysis bullosa (DEB).
According to filings B-VEC manufacturer Krystal Biotech disclosed to the U.S. Securities and Exchange Commission, the likely annual price of therapy could be between $200,000

The FDA’s broad indication for the use of beremagene geperpavec therapy for the treatment of dystrophic epidermolysis bullosa may have large financial implications for payers, according to a study.
In May 2023, the FDA approved the first topical gene therapy, beremagene geperpavec (B-VEC; Vyjuvek, Krystal Biotech), for the treatment of autosomal recessive and autosomal dominant dystrophic epidermolysis bullosa (DEB).
According to filings B-VEC manufacturer Krystal Biotech disclosed to the U.S. Securities and Exchange Commission, the likely annual price of therapy could be between $200,000